BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) rose 13.8% during trading on Tuesday . The company traded as high as $4.79 and last traded at $4.77, with a volume of 1,610,615 shares. The stock had previously closed at $4.19.

BCRX has been the topic of a number of recent analyst reports. Zacks Investment Research cut shares of BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, April 11th. HC Wainwright restated a “buy” rating on shares of BioCryst Pharmaceuticals in a research note on Friday. FBR & Co reiterated a “buy” rating and set a $6.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Wednesday, July 6th. JMP Securities cut shares of BioCryst Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Thursday, August 4th. Finally, Jefferies Group lifted their price objective on shares of BioCryst Pharmaceuticals from $2.00 to $3.00 and gave the company a “hold” rating in a research report on Friday. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $8.60.

The firm’s 50 day moving average is $3.16 and its 200-day moving average is $3.27. The stock’s market capitalization is $364.78 million.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its earnings results on Thursday, August 4th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.04. During the same period last year, the business earned $0.06 earnings per share. The company earned $4.80 million during the quarter, compared to analyst estimates of $3.92 million. The firm’s revenue was down 81.4% compared to the same quarter last year. Analysts anticipate that BioCryst Pharmaceuticals Inc. will post ($1.04) EPS for the current fiscal year.

Other hedge funds recently modified their holdings of the company. Jennison Associates LLC increased its stake in shares of BioCryst Pharmaceuticals by 1.8% in the fourth quarter. Jennison Associates LLC now owns 1,348,563 shares of the biotechnology company’s stock worth $13,917,000 after buying an additional 24,014 shares during the period. Globeflex Capital L P bought a new stake in shares of BioCryst Pharmaceuticals during the fourth quarter worth about $1,241,000. Finally, Morgan Stanley increased its stake in shares of BioCryst Pharmaceuticals by 13.9% in the fourth quarter. Morgan Stanley now owns 103,804 shares of the biotechnology company’s stock worth $1,071,000 after buying an additional 12,646 shares during the period.

BioCryst Pharmaceuticals, Inc (BioCryst) is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. The Company uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.